GO
Loading...

Pharmaceuticals

More

  • CNBC's Dan Scott: Novartis Drug Galvus Could be Delayed Tuesday, 20 Feb 2007 | 10:39 AM ET

    Swiss pharmaceutical giant Novartis' plans to launch diabetes treatment Galvus may be dealt a blow by the Food and Drug Administration at the end of the month, market sources told CNBC Europe.

  • Merck CFO to Retire in July Tuesday, 20 Feb 2007 | 9:59 AM ET

    Merck said Chief Financial Officer Judy Lewent, 58, plans to retire in July after 17 years in the post.

  • Shire Buying New River Pharmaceuticals Tuesday, 20 Feb 2007 | 7:23 AM ET

    British pharmaceutical company Shire, which makes ADHD drug Adderall XR, said Tuesday it is buying U.S. drug maker New River Pharmaceuticals  for approximately $2.6 billion, or $64 per share in cash.

  • Elan reported a smaller fourth-quarter loss and higher sales Tuesday, citing the expansion of its multiple sclerosis-fighting drug Tysabri as a major factor.

  • A Valentine For Onyx Tuesday, 13 Feb 2007 | 2:22 PM ET

    Onyx Pharmaceuticals is up big for the second day in a row. The stock nearly doubled yesterday on astronomical volume of 56,000,000 shares and today as I write this it's up almost 8% with more than 18,000,000 shares changing hands. So, what's up besides the stock?

  • Sanofi Tops Forecast, No Comment on Bristol Tuesday, 13 Feb 2007 | 4:18 AM ET

    Sanofi-Aventis  posted higher-than-expected fourth-quarter current operating profit, despite healthcare savings in Europe as well as generic rivalry, and the drugmaker predicted more growth for 2007.

  • Cytyc Corp. to Buy Adeza Biomedical for $452 Million Monday, 12 Feb 2007 | 12:06 PM ET

    Cytyc's $24-a-share offer represents a 55% premium over the $15.53 closing price of Adeza's shares Friday on the Nasdaq Stock Market.

  • Shares of  Onyx Pharmaceuticals  soared Monday after it and its partner Bayer  reported positive results from the final trial of a treatment for advanced liver cancer, paving the way for approval of the drug.

  • Bristol-Myers shares have run up strongly in the past two weeks on talk of a Sanofi bid, closing at $28.52 on Friday to value Bristol-Myers at more than $56 billion.

  • A New "Alli" From Glaxo Thursday, 8 Feb 2007 | 5:25 PM ET

    GlaxoSmithKline has won FDA approval to sell the formerly prescription-only diet drug Xenical over-the-counter.  The drug can help people lose, on average, about six pounds.  It'll be called "Alli" (pronounced like "ally"). GSK will split the profits with Roche, which owns prescription Xenical. ... An analyst says Alli could have peak sales of $100 million to $300 million, which would be a blockbuster by OTC-drug standards.

  • GlaxoSmithKline Posts 16% Rise in Full-Year Profit Thursday, 8 Feb 2007 | 8:08 AM ET

    GlaxoSmithKline, Europe's biggest drug maker, reported a 16% rise in annual profit Thursday, in line with expectations of analysts polled by Reuters. But the company said 2007 growth would slow as it awaits pipeline renewal.

  • Tamiflu Fever Wednesday, 7 Feb 2007 | 2:14 PM ET

    Roche reported today that it sold $2.1 billion worth of Tamiflu last year (a 68% increase). Tamiflu is the antiviral that you take shortly after you feel like you've got the flu or as a prophylactic if someone literally close to you has it. But the main driver behind the sales spike last year was government stockpiling of the drug in case of a pandemic.

  • Roche Net Profit up 34% on Cancer Drug Sales Wednesday, 7 Feb 2007 | 10:32 AM ET

    Net profit at Roche Holding rose 34% to 9.17 billion Swiss francs ($7.33 billion) in 2006 due to strong sales of cancer treatments Herceptin and Avastin, just ahead of analysts' expectations.

  • Bird flu returned to the headlines recently as 159,000 turkeys were slaughtered in a Suffolk, U.K. farm in a confirmed avian influenza (H5N1) outbreak.

  • Gardasil: On Guard Tuesday, 6 Feb 2007 | 10:54 AM ET

    The Governor of Texas announced on Friday that all girls entering the sixth grade in his state must get Merck's new vaccine, Gardasil, before they can enroll. Gardasil prevents four strains of the sexually-transmitted disease known as HPV which is the leading cause of cervical cancer. It works best when given before becoming sexually active. But the political and social backlash has already begun.

  • Bayer Plans to Invest $1.8B in Shanghai Tuesday, 6 Feb 2007 | 4:13 AM ET

    Bayer MaterialSience AG will increase its capacity at a planned facility in Shanghai, investing around $1.8 billion (1.4 billion euros) in the plant, the company said Tuesday.

  • Ethical Debates Bog Down Merck's Vaccine Monday, 5 Feb 2007 | 2:59 PM ET

    Gov. Rick Perry of Texas recently ordered that all girls entering the sixth grade in that state be vaccinated against cervical cancer. The mandate has become a source of controversy from more than one angle. Does a governor have the right to make such an order? Is the vaccine safe? Could it promote sexual promiscuity? What role does Merck – the company that developed and produces the vaccine – play in all this?

  • AstraZeneca To Ax 3,000; Blames Generics Friday, 2 Feb 2007 | 12:14 PM ET

    When Pfizer announced its deeper cost cuts last week, including a total of about 10,000 layoffs, analysts said other big drug companies that had not already started restructuring would use the industry giant as the model. Sure enough, today AstraZeneca said it will get rid of 3,000 employees (5% of its workforce) over the next few years. Also: Gilead shares at record high.

  • Judge Dismisses Wyeth Hormone Replacement Case Friday, 2 Feb 2007 | 10:33 AM ET

    Wyeth said Judge Caroline E. Baker of the Harris County District Court in Houston granted its motion for summary judgment and dismissed the case of Brockert v. Wyeth, which was to have begun trial on Monday.

  • Bristol Shares Climb On Sanofi Merger Rumor Thursday, 1 Feb 2007 | 1:50 PM ET

    If the report is true, Sanofi-Aventis and Bristol-Myers Squibb could soon merge to create the world's biggest drug company.  (Pfizer's No. 1 today.)  The story comes out of a French financial "newsletter" which attributed the information to no one -- but the market seemed to put some credence into the report. Also: stay tuned for pharma earnings on Tuesday and Wednesday.

Most Popular Video

Thursday, 17 Apr 2014 | 6:40 PM ET

Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.

Thursday, 17 Apr 2014 | 6:30 PM ET

The latest cybersecurity headlines- tax scammers have no deadline, and the Heartbleed vulnerability threatens websites. CNBC's Scott Cohn reports.

Thursday, 17 Apr 2014 | 6:25 PM ET

John McAvoy, president and CEO of Consolidated Edison, discusses the state of the business with Mad Money host Jim Cramer.